1. ALLA AKTIER
  2. NYHETER
  3. SANIONA

Saniona

Nyheter Saniona Nyheter alla bolag
eToro Trading Platform Advertisement
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Saniona publishes its Annual Report for 2022

MAR

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels today announced that the English version of the Annual Report for 2022 is now available on the company’s website, www.saniona.com.

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. Saniona’s most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity by Saniona’s partner Medix. Saniona is advancing four product candidates including Tesomet™ and three ion channel modulators SAN711, SAN903 and SAN2219. Tesomet™ has progressed to mid-stage clinical trials for rare eating disorders. SAN711 has completed Phase 1 for neuropathic pain conditions. SAN903 is ready for Phase 1 for inflammatory and fibrotic disorders. SAN2219 is in preclinical development for epilepsy. Saniona has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cephagenix ApS. Saniona is based in Copenhagen, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

This information is information that Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-28 12:45 CEST.

Attachments
SANIONA Annual Report UK 2022

Datum 2023-04-28, kl 12:45
Källa MFN
Bifogade filer
SANIONA Annual Report UK 2022